Theravance Biopharma (TBPH) FCF Margin (2013 - 2026)
Theravance Biopharma (TBPH) reported FCF Margin of 414.03% for Q1 2026, up 13434.0% year-over-year from N/an in Q1 2025, and up 1804.67% quarter-over-quarter from 24.29% in Q4 2025.
Theravance Biopharma (TBPH) FCF Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of FCF Margin data on file, last reported at 414.03% in Q1 2026.
- FCF Margin for Q1 2026 came in at 414.03%, up 13434.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 302.39% (up 25292.0% YoY), and the FY2025 annual result was 3179.99%, up 319842.0% from the prior year.
- FCF Margin improved to 414.03% in Q1 2026 per TBPH's latest filing, from 24.29% in the prior quarter.
- Over five years, FCF Margin peaked at 794.33% in Q2 2025 and troughed at 1052.76% in Q1 2022.
- A 5-year average of 64.42% and a median of 30.89% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin plunged 56178 bps in 2022, then soared 93604 bps in 2023.
- A 5-year view of FCF Margin shows it stood at 848.67% in 2022, then surged by 99 bps to 8.72% in 2023, then surged by 33 bps to 5.82% in 2024, then plunged by 317 bps to 24.29% in 2025, then jumped by 1805 bps to 414.03% in 2026.
- Business Quant data shows TBPH's FCF Margin at 414.03% in Q1 2026, 24.29% in Q4 2025, and 32.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | 414.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 414.03% |
| Dec 31, 2025 | -24.29% |
| Sep 30, 2025 | -32.56% |
| Jun 30, 2025 | 794.33% |
| Mar 31, 2025 | 279.69% |
| Dec 31, 2024 | -5.82% |
| Sep 30, 2024 | -30.89% |
| Jun 30, 2024 | -31.22% |
| Mar 31, 2024 | -7.67% |
| Dec 31, 2023 | -8.72% |
| Sep 30, 2023 | -15.98% |
| Jun 30, 2023 | -96.65% |
| Mar 31, 2023 | -116.72% |
| Dec 31, 2022 | -848.67% |
| Sep 30, 2022 | -180.46% |
| Jun 30, 2022 | -130.81% |
| Mar 31, 2022 | -1,052.76% |
| Dec 31, 2021 | -286.89% |
| Sep 30, 2021 | -352.32% |
| Jun 30, 2021 | -389.26% |